- Building on Pfizer’s longstanding commitment to fight infectious diseases, grants will help address urgent needs of U.S. and global partners on the front lines of the pandemic
- Donations complement Pfizer’s COVID-19 R&D investments, as well as collective scientific and philanthropic contributions made by the biopharmaceutical industry
- U.S. Patient Assistance Program and other programs respond to changing needs of patients and medical community
The Pfizer Foundation has announced that it had committed $40 million in medical and charitable cash grants to help combat the global health effects of the COVID-19 pandemic in the U.S. and around the world.
The donation addresses the urgent needs of partners who are working to slow the spread of the virus within communities and strengthen vulnerable healthcare systems against future public health threats. Pfizer is also responding to patient and healthcare provider needs during this unprecedented time by evolving its U.S. Patient Assistance Program and donating additional critical medicines and vaccines in the U.S. and around the world. The combined donation includes medical and charitable grants from Pfizer Inc. and The Pfizer Foundation to support both U.S. and global responses to COVID-19 efforts.
Published: 6th April 2020.